Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Sell
45
GNOM Quote, Financials, Valuation and Earnings
Last price:
$9.95
Seasonality move
:
-11.63%
Day range:
$10.20 - $10.34
52-week range:
$9.52 - $12.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
61.8K
Avg. volume:
82.5K
1-year change:
-11.98%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
-- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
$10.29 | -- | -- | -- | $0.00 | 0% | -- |
|
AGNG
Global X Aging Population ETF
|
$30.42 | -- | -- | -- | $0.15 | 0.82% | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$24.27 | -- | -- | -- | $0.24 | 0.99% | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
$10.18 | -- | -- | -- | $0.00 | 0% | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
$29.67 | -- | -- | -- | $0.00 | 0% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$68.92 | -- | -- | -- | $0.01 | 0.05% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 2.174 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 1.018 | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.540 | -- | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
-- | 1.617 | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | 1.470 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 1.078 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
-- | -- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
Global X Genomics & Biotechnology ETF vs. Competitors
-
Which has Higher Returns GNOM or AGNG?
Global X Aging Population ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About GNOM or AGNG?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Global X Aging Population ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is GNOM or AGNG More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.142, which suggesting that the stock is 14.178% more volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.780, suggesting its less volatile than the S&P 500 by 21.991%.
-
Which is a Better Dividend Stock GNOM or AGNG?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Global X Aging Population ETF offers a yield of 0.82% to investors and pays a quarterly dividend of $0.15 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or AGNG?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns GNOM or BBC?
Virtus LifeSci Biotech Clinical Trials ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Virtus LifeSci Biotech Clinical Trials ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -
What do Analysts Say About GNOM or BBC?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Clinical Trials ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Virtus LifeSci Biotech Clinical Trials ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Virtus LifeSci Biotech Clinical Trials ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 -
Is GNOM or BBC More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.142, which suggesting that the stock is 14.178% more volatile than S&P 500. In comparison Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.042, suggesting its more volatile than the S&P 500 by 4.196%.
-
Which is a Better Dividend Stock GNOM or BBC?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Virtus LifeSci Biotech Clinical Trials ETF offers a yield of 0.99% to investors and pays a quarterly dividend of $0.24 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Clinical Trials ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or BBC?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Virtus LifeSci Biotech Clinical Trials ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Clinical Trials ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Virtus LifeSci Biotech Clinical Trials ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- --
-
Which has Higher Returns GNOM or EDOC?
Global X Telemedicine & Digital Health ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Global X Telemedicine & Digital Health ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- EDOCGlobal X Telemedicine & Digital Health ETF-- -- -- -
What do Analysts Say About GNOM or EDOC?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Telemedicine & Digital Health ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Global X Telemedicine & Digital Health ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Global X Telemedicine & Digital Health ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 EDOCGlobal X Telemedicine & Digital Health ETF0 0 0 -
Is GNOM or EDOC More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.142, which suggesting that the stock is 14.178% more volatile than S&P 500. In comparison Global X Telemedicine & Digital Health ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GNOM or EDOC?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Global X Telemedicine & Digital Health ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Global X Telemedicine & Digital Health ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or EDOC?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Global X Telemedicine & Digital Health ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Global X Telemedicine & Digital Health ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Global X Telemedicine & Digital Health ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Global X Telemedicine & Digital Health ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- EDOCGlobal X Telemedicine & Digital Health ETF-- -- -- --
-
Which has Higher Returns GNOM or HTEC?
ROBO Global Healthcare Technology & Innovation ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat ROBO Global Healthcare Technology & Innovation ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -
What do Analysts Say About GNOM or HTEC?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ROBO Global Healthcare Technology & Innovation ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than ROBO Global Healthcare Technology & Innovation ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than ROBO Global Healthcare Technology & Innovation ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 -
Is GNOM or HTEC More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.142, which suggesting that the stock is 14.178% more volatile than S&P 500. In comparison ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.075, suggesting its more volatile than the S&P 500 by 7.497%.
-
Which is a Better Dividend Stock GNOM or HTEC?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ROBO Global Healthcare Technology & Innovation ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. ROBO Global Healthcare Technology & Innovation ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or HTEC?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than ROBO Global Healthcare Technology & Innovation ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than ROBO Global Healthcare Technology & Innovation ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while ROBO Global Healthcare Technology & Innovation ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for ROBO Global Healthcare Technology & Innovation ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- --
-
Which has Higher Returns GNOM or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About GNOM or PBE?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is GNOM or PBE More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.142, which suggesting that the stock is 14.178% more volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.828, suggesting its less volatile than the S&P 500 by 17.198%.
-
Which is a Better Dividend Stock GNOM or PBE?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invesco Biotechnology & Genome ETF offers a yield of 0.05% to investors and pays a quarterly dividend of $0.01 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or PBE?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Marvell Stock Up?
Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…
Why Is General Electric Stock Going Up?
General Electric Company, doing business these days as GE Aerospace…
Stock Ideas
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
1
IONQ alert for Jan 10
IonQ [IONQ] is up 7.07% over the past day.
Sell
47
CEG alert for Jan 10
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
8
CRNX alert for Jan 10
Crinetics Pharmaceuticals [CRNX] is down 16.31% over the past day.
